InspireMD Q3 revenue record $2.5M (+39% YoY) as U.S. CGuard Prime launch gains traction

InspireMD, Inc.

2025-Q3 EPS reported -$0.64 revenue$5,830,000

U.S. revenue of $497k marks first commercial quarter for CGuard Prime carotid stent system.
Net loss $12.7M ($0.17/share) vs $7.9M ($0.16) a year ago; operating expenses up 57% on U.S. expansion.
Cash and marketable securities $63.4M at Sep 30, up from $34.6M at Dec 31, 2024, boosted by $58M July offering.
Over 100 U.S. carotid procedures completed; appointed Peter A. Soukas, M.D. as CMO and Dan Dearen to board.
Gross profit nearly doubled to $864k on favorable shift toward higher-margin U.S. sales.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.